A 2025 clinical trial adds new evidence to the conversation about collagen peptides and joint health. Published in Joint Diseases and Related Surgery, the study was designed with the strongest standard of evidence available for a nutrition supplement trial: it was double-blind, randomized, and placebo-controlled, meaning neither participants nor researchers knew who received the active supplement until the results were analyzed.

What the research looked at

The trial examined a supplement combining type 1 and type 3 collagen peptides together with type 2 hydrolyzed collagen. Researchers were interested in three related questions that matter to people living with osteoarthritis: whether the supplement affected joint pain, whether it made a measurable difference to quality of life, and whether it influenced physical function — the ability to move, bend, and carry out everyday activities without being limited by joint discomfort.

What it found

The study reported associations between the collagen peptide combination and improvements across these outcomes: osteoarthritis-related pain, quality of life, and physical function. Taken together, this trial adds to a growing body of evidence suggesting that collagen peptides, when taken consistently over time, can support joint comfort and everyday function. It joins a wider set of published research exploring how different collagen types may work together to support the joint.

What it means (and the limits)

It's worth reading these results the way careful researchers do: as one more data point, not a final verdict. A single trial, however well designed, cannot answer every question about dosing, duration, or which populations benefit most. As with any joint-health supplement, the pattern seen across this and other studies is consistent — benefits tend to build gradually over weeks to months rather than appearing overnight, and individual responses vary from person to person. Collagen peptides are a nutritional supplement intended to support joint comfort and function over time; they are not a cure for osteoarthritis or a substitute for medical care.

For anyone considering a joint-support supplement, this kind of research is useful context: it points to collagen peptides — combining type 1, type 3, and hydrolyzed type 2 forms — as an area worth continued study, with encouraging but not definitive findings on pain, quality of life, and physical function.

Sources: https://www.jointdrs.org/full-text/1642

Dual-action joint collagen

Mafsal Riyadi combines the two collagen types most studied for joints — high-tripeptide hydrolyzed collagen and undenatured type II collagen — in one licensed dietary supplement (EDA reg. no. 14711/2026). Research about ingredient categories is general and is not a claim about any individual product.

Learn about Mafsal Riyadi

This is a plain-language summary of published research for general education. It is not medical advice, a diagnosis, or a treatment recommendation, and individual studies have limitations. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Consult your doctor or pharmacist about your own situation.